Disease · MONDO_0016537
lymphoproliferative syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. lymphoproliferative syndrome. Diseases, record MONDO_0016537. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016537
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TABELECLEUCEL | CHEMBL3990008 | Cell | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| ARGININE BUTYRATE | CHEMBL6067996 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| INTERFERON ALFA-2A | CHEMBL2108508 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| IXABEPILONE | CHEMBL1201752 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEFLUNOMIDE | CHEMBL960 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEGINTERFERON ALFA-2A | CHEMBL1201560 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| TRETINOIN | CHEMBL38 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VALGANCICLOVIR | CHEMBL1201314 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 1/2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets36
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IFNAR1 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| ACVR1 | Activin receptor type-1 | 1 | Activin receptor type-1 inhibitor | Phase 1 | https://conductscience.org/library/genes/90 | Drugs and targets |
| BCL2 | Apoptosis regulator Bcl-2 | 1 | Apoptosis regulator Bcl-2 inhibitor | Phase 1 | https://conductscience.org/library/genes/596 | Drugs and targets |
| BCL2L1 | Bcl-2-like protein 1 | 1 | Apoptosis regulator Bcl-X inhibitor | Phase 1 | https://conductscience.org/library/genes/598 | Drugs and targets |
| BCL2L2 | Bcl-2-like protein 2 | 1 | Apoptosis regulator Bcl-W inhibitor | Phase 1 | https://conductscience.org/library/genes/599 | Drugs and targets |
| BCL2L2-PABPN1 | Bcl-2-like protein 2 | 1 | Apoptosis regulator Bcl-W inhibitor | Phase 1 | https://conductscience.org/library/genes/100529063 | Drugs and targets |
| CD2 | T-cell surface antigen CD2 | 1 | T-cell surface antigen CD2 inhibitor | Phase 1 | https://conductscience.org/library/genes/914 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1/2 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1/2 | https://conductscience.org/library/genes/8451 | Drugs and targets |
1 to 10 of 36
See all 36 targetsTrials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Phase 1 | 38 | 2025-02-24 | Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease, Nasopharyngeal Carcinoma, Smooth Muscle Tumor | CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04463615 | Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders | Phase 2 | 1 | 2023-12-05 | Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder | LEFLUNOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT07133763 | Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. | Phase 1/2 | 50 | EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide, Lenalidomide | LENALIDOMIDE, TENOFOVIR, TUCIDINOSTAT | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03258567 | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | Phase 2 | 40 | Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder, Disorders, Lymphoproliferative | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00052572 | Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders | Phase 2 | 35 | Leukemia, Lymphoma | IXABEPILONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00123942 | Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease | Phase 1 | 31 | Lymphoproliferative Disorders | SIPLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00001438 | A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes | Phase 2 | 30 | HIV Infections, Immunologic Deficiency Syndromes, Lymphoproliferative Disorders | TRETINOIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00788684 | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers | Phase 1 | 29 | CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma | NAVITOCLAX, RITUXIMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00064246 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | Phase 1/2 | 28 | Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Waldenström Macroglobulinemia | IBRITUMOMAB TIUXETAN, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Phase 1 | 4 | Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma | PACRITINIB | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016537
GET https://conductscience.org/api/diseases/v1/MONDO_0016537/drugs?page=2